Farah Husain, PA
Medical · Frisco, TXNPI 1639303308
Payments from drug & device makers
Across 240 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$730
- Lilly USA, LLC$457
- Abbott$443
- Xeris Pharmaceuticals, Inc.$360
- Mannkind Corporation$354
- Tandem Diabetes Care, Inc.$288
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,195100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $730 |
| Lilly USA, LLC | 29 | $457 |
| Abbott | 18 | $443 |
| Xeris Pharmaceuticals, Inc. | 19 | $360 |
| Mannkind Corporation | 20 | $354 |
| Tandem Diabetes Care, Inc. | 8 | $288 |
| Cequr Corporation | 4 | $255 |
| Amgen | 8 | $220 |
| Corcept Therapeutics | 8 | $198 |
| Sanofi-aventis U.S. LLC | 10 | $180 |
| Radius Health, Inc. | 9 | $171 |
| Boehringer Ingelheim | 8 | $147 |
| Amneal Pharmaceuticals LLC | 7 | $145 |
| Sequel Med Tech, LLC | 2 | $134 |
| Dexcom, Inc. | 6 | $117 |
| Medtronic | 5 | $112 |
| IBSA Pharma Inc. | 5 | $104 |
| Bayer | 5 | $96 |
| Insulet Corporation | 4 | $83 |
| AbbVie | 5 | $78 |
| BETA Bionics, Inc. | 4 | $76 |
| Amarin Pharma, Inc. | 3 | $60 |
| Amryt Pharma Holdings Ltd | 3 | $59 |
| Antares Pharma, Inc. | 3 | $53 |
| Zealand Pharma US, Inc. | 3 | $50 |
| Merck | 2 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $27 |
| AstraZeneca | 1 | $23 |
| Chiesi USA, Inc. | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$178
- t:slim X2 Insulin Pump with Control-IQ$124
- TWIIST$111
- Ozempic$110
- EVENITY$103
How this compares
$5,195 in reported general payments places this provider in the 85th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $343,067 |
| MounjaroTirzepatide | 60 | $103,032 |
| FarxigaDapagliflozin Propanediol | 77 | $92,580 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 45 | $63,474 |
| TrulicityDulaglutide | 23 | $54,925 |
| JardianceEmpagliflozin | 35 | $48,833 |
| ForteoTeriparatide | 12 | $46,698 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $45,482 |
| Xigduo XrDapaglifloz Propaned/Metformin | 16 | $25,117 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $22,440 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $20,023 |
| TradjentaLinagliptin | 12 | $15,696 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $15,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,803 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 47 | $5,367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $730 | $343,067171 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $457 | $204,65595 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $147 | $128,00392 claims |
| AstraZenecaFarxiga | $23 | $92,58077 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $145 | $3,452194 claims |
| AbbVieSynthroid | $78 | $2,90926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,490 medical providers in Texas.
Other medical in Frisco
- Adrianne BaileyFrisco$22K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.